Forum Topic News
  • Conversation: Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients

    • January 21, 2019 12:10 PM GMT
    • Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirum...

      REACH-2 is a global, randomized, double-blind, placebo-controlled Phase 3 study of CYRAMZA and best supportive care (BSC) compared to placebo and BSC in hepatocellular carcinoma (HCC) patients who were intolerant to, or who had disease progression while on or following treatment with, sorafenib and had a high alpha-fetoprotein (AFP-High), defined as an AFP of ≥400 ng/mL.
      Initiated in 2015, the study has enrolled 292 patients across 20 countries in North America, Asia, Europe and Latin America. Patients were assigned to 8 mg/kg of intravenous CYRAMZA (n=197) or placebo (n=95) at every two weeks until disease progression, unacceptable toxicity, or withdrawal of consent, with all patients receiving BSC. The primary endpoint of the REACH-2 trial is overall survival (OS) and key secondary endpoints include progression-free survival, objective response rate, quality of life and safety.
      Read more: https://prn.to/2HnKexP

Add Reputation

Do you want to add reputation for this member by this post?

or cancel